EMPA-Kidney Seals SGLT2 Inhibitors as 'Foundational' for CKD
Empagliflozin's efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.
Source: medscape.com